



BioCorporate profile downloaded from - <http://www.bioportfolio.com> on Thursday, November 26, 2009

## OSI Pharmaceuticals

[View the current OSI Pharmaceuticals Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/7940-OSI+Pharmaceuticals.html)

(<http://www.bioportfolio.com/biocorporate/7940-OSI+Pharmaceuticals.html>)

### Contact Details:

**41 Pinelawn Road**

**Melville,**

**NY**

**11747**

**United States of America**

Tel: (631) 962-2000

Fax: (631) 752-3880

Email: [investor\\_info@osip.com](mailto:investor_info@osip.com)

OSI Pharmaceuticals is committed to “shaping medicine and changing lives” by developing and commercializing high-quality and novel pharmaceutical products that extend life or improve the quality of life for patients with cancer, diabetes, and obesity. We specialize in the discovery and development of innovative molecular targeted therapies that address significant unmet medical needs, and strive to turn pioneering science into breakthrough therapies for patients suffering from life-threatening diseases. Our Oncology business is anchored by our flagship product, Tarceva® (erlotinib), a small molecule inhibitor of the epidermal growth factor receptor, or EGFR, that was first discovered and developed by OSI. Tarceva is the only EGFR inhibitor to have demonstrated the ability to improve overall survival in advanced non-small cell lung cancer and advanced pancreatic cancer. Behind Tarceva, we have an emerging oncology pipeline of molecular targeted therapies in clinical and late-stage pre-clinical development. Our R & D strengths include high-throughput screening, chemical libraries, medicinal and combinational chemistry and automated drug profiling technology platforms. Our diabetes and obesity R & D programs are conducted through Prosidion Limited, our U.K. subsidiary dedicated to the discovery and development of novel therapies for metabolic diseases, particularly type 2 diabetes and obesity. (OSI) Prosidion has an emerging diabetes and obesity clinical pipeline with several innovative drug candidates that have progressed into clinical development. OSI has a dedicated team of approximately 500 research and development, regulatory, sales, marketing, commercial, and business professionals. We are headquartered in Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. Our Flagship Product Tarceva (erlotinib) is a small molecule human epidermal growth factor type 1/epidermal growth factor receptor (HER1/EGFR) inhibitor which is currently marketed for the treatment of non-small cell lung cancer and pancreatic cancer. Products and Pipeline A key to our long-term success resides in our ability to continue to fund our deep and innovative pipeline, both to enhance the Tarceva franchise and seed high-quality research programs in oncology, diabetes and obesity.

- [High-Throughput Screening for mTORC1/mTORC2 Kinase Inhibitors Using a Chemiluminescence-Based ELISA Assay.](#)  
*A high-throughput chemiluminescence and ELISA-based biochemical assay to...* 10th November, 2009  
Department of Cancer Biology, OSI Pharmaceuticals Inc., Farmingdale, New- Assay Drug Dev Technol. 2009 Oct;7(5):471-478. ([DOI Direct Link](#))
- [Prognostic factors versus predictive factors: Examples from a clinical trial of erlotinib.](#)  
*It would be helpful to have factors that could identify patients who will,...* 30th May, 2009  
Biostatistics and Data Management, OSI Pharmaceuticals, Inc., 2860- Mol Oncol. 2008 Apr;1(4):406-12. Epub 2007 Dec 8. ([DOI Direct Link](#))
- [Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy.](#)  
*NSCLC cells with a mesenchymal phenotype have shown a marked reduction in...* 14th January, 2009  
Department of Translational Research, OSI Pharmaceuticals Inc., 1- Clin Exp Metastasis. 2008;25(8):843-54. Epub 2008 Aug 12. ([DOI Direct Link](#))
- [Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.](#)  
*Epidermal growth factor receptor (EGFR) and insulin-like growth factor-I...* 8th November, 2008  
Translational Research, Cancer Biology, OSI Pharmaceuticals, Farmingdale,- Cancer Res. 2008 Oct 15;68(20):8322-32. ([DOI Direct Link](#))
- [Cytochrome P450 oxidation of the thiophene-containing anticancer drug 3-\[\(quinolin-4-ylmethyl\)-amino\]-thiophene-2-carboxylic acid \(4-trifluoromethoxy-phenyl\)-amide to an electrophilic intermediate.](#)  
*Compounds that are enzymatically transformed to reactive intermediates are...* 10th October, 2008  
Drug Metabolism and Pharmacokinetics, OSI Pharmaceuticals, Boulder,- Chem Res Toxicol. 2008 Aug;21(8):1570-7. Epub 2008 Aug 2. ([DOI Direct Link](#))
- [Bypassing cellular EGF receptor dependence through epithelial-to-mesenchymal-like transitions.](#)  
*Over 90% of all cancers are carcinomas, malignancies derived from cells of...* 17th September, 2008  
OSI Pharmaceuticals Inc., 1 Bioscience Park Dr., Farmingdale, NY 11735,- Clin Exp Metastasis. 2008;25(6):685-93. Epub 2008 Jan 31. ([DOI Direct Link](#))
- [Many drugs and phytochemicals can be activated to biological reactive intermediates.](#)  
*The metabolism of drugs and other xenobiotics is exemplified by cytochrome...* 1st July, 2008  
Drug Metabolism and Pharmacokinetics, OSI Pharmaceuticals, Boulder, CO- Curr Drug Metab. 2008 May;9(4):344-51.
- [Quantitative high-throughput cell-based assays for inhibitors of ROCK kinases.](#)  
*The serine/threonine kinases ROCK1 and ROCK2 are direct targets of...* 21st June, 2008  
OSI Pharmaceuticals, Farmingdale, New York, USA.- Methods Enzymol. 2008;439:491-500. ([DOI Direct Link](#))
- [Novel 2-phenylquinolin-7-yl-derived imidazo\[1,5-a\]pyrazines as potent insulin-like growth factor-I receptor \(IGF-IR\) inhibitors.](#)  
*A series of novel, potent quinolinyl-derived imidazo[1,5-a]pyrazine IGF-IR...* 29th April, 2008  
(OSI) Oncology, OSI Pharmaceuticals, Inc., 41 Pinelawn Road, Melville, NY- Bioorg Med Chem. 2008 Feb 1;16(3):1359-75. Epub 2007 Oct 23. ([DOI Direct Link](#))
- [Cytochrome P450 inactivation by pharmaceuticals and phytochemicals: therapeutic relevance.](#)  
*One of the major clinical concerns is possible drug interactions that can...* 7th March, 2008  
Drug Metabolism and Pharmacokinetics, OSI Pharmaceuticals, Boulder,- Drug Metab Rev. 2008;40(1):101-47. ([DOI Direct Link](#))

- [Local tolerance and systemic safety of pegaptanib sodium in the dog and rabbit.](#)  
*PURPOSE: To evaluate the local tolerance, systemic toxicity, and...*17th January, 2008  
(OSI) Pharmaceuticals,- J Ocul Pharmacol Ther. 2007 Oct;23(5):452-66. ([DOI Direct Link](#))
- [A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo.](#)  
*Insulin-like growth factor-I receptor (IGF-IR) and its ligands, IGF-I and...*16th October, 2007  
Oncology, OSI Pharmaceuticals,- Mol Cancer Ther. 2007 Aug;6(8):2158-67. Epub 2007 Aug 1. ([DOI Direct Link](#))
- [Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies.](#)  
*PURPOSE: Data from two large phase III studies were analyzed to...*7th September, 2007  
OSI Pharmaceuticals,- Clin Cancer Res. 2007 Jul 1;13(13):3913-21. ([DOI Direct Link](#))
- [Reprogramming the histone code.](#)  
*INTRODUCTION: Erlotinib (Tarceva) has demonstrated a survival benefit in...*15th June, 2007  
OSI Pharmaceuticals Inc., 1 Bioscience Park Drive, Farmingdale, NY 11735,- Chem Biol. 2007 Mar;14(3):242-4. ([DOI Direct Link](#))
- [Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib.](#)  
*INTRODUCTION: Erlotinib (Tarceva) has demonstrated a survival benefit in...*15th May, 2007  
OSI Pharmaceuticals,- J Thorac Oncol. 2006 Oct;1(8):837-46.

#### Press Releases on OSI Pharmaceuticals:

<a href="#">Onyx Pharmaceuticals Announces December 2009 Investor Events</a>	25th November, 2009	Onyx Pharmaceuticals, Inc.	EMERYVILLE, Calif., Nov. 25 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the company will host two investor events in December: ASH Briefing December 7, SAN DIEGO, Nov. 25
<a href="#">Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference</a>	25th November, 2009	Ardea Biosciences, Inc.	/PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that Barry D. Quart, Pharm.D., president and chief executive officer, will present at the Piper DELFT, The Netherlands and JOHANNESBURG, November 25 /PRNewswire/ -- iThemba Pharmaceuticals
<a href="#">iThemba Pharmaceuticals (Pty) Ltd and Pyxis Discovery B.V. Announce Collaborative Agreement to Offer a Combined Service Offering</a>	25th November, 2009		's service division and Pyxis Discovery announced today that they have signed a collaborative agreement

[Reportlinker Adds  
Cell/Tissue Culture  
Supplies - A Global  
Market Perspective](#)

25th November,  
2009 Reportlinker

NEW YORK, Nov. 25  
/PRNewswire/ --  
Reportlinker.com announces  
that a new market research  
report is available in its  
catalogue: Cell/Tissue Culture  
Supplies - A Global Market  
Perspective <http://www>

[Reportlinker Adds  
Intranasal Drug Delivery -  
US Market Trends &  
Analysis](#)

25th November,  
2009 Reportlinker

NEW YORK, Nov. 25  
/PRNewswire/ --  
Reportlinker.com announces  
that a new market research  
report is available in its  
catalogue: Intranasal Drug  
Delivery - US Market Trends &  
Analysis <http://www>

## BioNews Results for OSI Pharmaceuticals



- [Updates for OSI Pharmaceuticals \(NASDAQ:OSIP\), Perrigo \(Nasdaq:PRGO\), Sensient \(NYSE:SXT\)](#)  
*California Chronicle: Nov 21 2009 8:29PM Matching: osi pharmaceuticals*
- [BiomedReports: News and FDA Updates for OSI Pharmaceuticals \(NASDAQ:OSIP\), Perrigo \(Nasdaq:PRGO\), Sensient \(NYSE:SXT\)](#)  
*Quote.com Japan: Nov 21 2009 11:46AM Matching: osi pharmaceuticals*
- [Updates for OSI Pharmaceuticals \(NASDAQ:OSIP\), Perrigo \(Nasdaq:PRGO\), Sensient \(NYSE:SXT\)](#)  
*Los Angeles Chronicle: Nov 21 2009 4:45AM Matching: osi pharmaceuticals*
- [Updates for OSI Pharmaceuticals \(NASDAQ:OSIP\), Perrigo \(Nasdaq:PRGO\), Sensient \(NYSE:SXT\)](#)  
*American Chronicle: Nov 21 2009 1:14AM Matching: osi pharmaceuticals*
- [BiomedReports: News and FDA Updates for OSI Pharmaceuticals \(NASDAQ:OSIP\), Perrigo \(Nasdaq:PRGO\), Sensient \(NYSE:SXT\)](#)  
*Individual.com: Nov 21 2009 2:43AM Matching: osi pharmaceuticals*
- [OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd](#)  
*SmartBrief: Nov 20 2009 6:49AM Matching: osi pharmaceuticals*
- [BiomedReports: News and FDA Updates for OSI Pharmaceuticals \(NASDAQ:OSIP\), Perrigo \(Nasdaq:PRGO\), Sensient \(NYSE:SXT\)](#)  
*TradingMarkets: Nov 20 2009 4:49PM Matching: osi pharmaceuticals*
- [OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd](#)  
*Individual.com: Nov 20 2009 8:41AM Matching: osi pharmaceuticals*
- [BiomedReports: News and FDA Updates for OSI Pharmaceuticals \(NASDAQ:OSIP\), Perrigo \(Nasdaq:PRGO\), Sensient \(NYSE:SXT\)](#)  
*TradingMarkets: Nov 20 2009 4:49PM Matching: osi pharmaceuticals*
- [OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd](#)  
*NewsBlaze: Nov 19 2009 4:06PM Matching: osi pharmaceuticals*
- [OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd](#)  
*Pharma Live: Nov 19 2009 8:39PM Matching: osi pharmaceuticals*
- [OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd](#)

- RBC Dain Rauscher: Nov 19 2009 4:04PM Matching: osi pharmaceuticals*
- [OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd](#)  
*FinanzNachrichten.de: Nov 19 2009 3:57PM Matching: osi pharmaceuticals*
  - [OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd](#)  
*Yahoo! Canada: Nov 19 2009 5:19PM Matching: osi pharmaceuticals*
  - [OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd](#)  
*Business Wire via Yahoo!: Nov 19 2009 4:55PM Matching: osi pharmaceuticals*

## OSI Pharmaceuticals Clinical Trials:



- [Study of OSI-211 Vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer](#)

## OSI Pharmaceuticals Patents:



- 6559309- [Preparation of a camptothecin derivative by intramolecular cyclisation](#)
- 6740335- [Liposomal camptothecin formulations](#)
- 6746852- [AGS proteins and nucleic acid molecules and uses thereof](#)
- 6800633- [Pyrrolo\[2,3d\]pyrimidine compositions and their use](#)
- 6821982- [Preparation of a camptothecin derivative by intramolecular cyclisation](#)
- 6869944- [Method for treating a patient with neoplasia by treatment with a platinum coordination complex](#)
- 6875575- [Diagnostic methods for neoplasia](#)
- 6878716- [Compounds specific to adenosine A1 receptor and uses thereof](#)
- 6900221- [Stable polymorph on N-\(3-ethynylphenyl\)-6, 7-bis \(2methoxyethoxy\)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof](#)
- 6916804- [Pyrimidine A2b selective antagonist compounds, their synthesis and use](#)
- 7064122- [Pancreatic lipase inhibitor compounds, their synthesis and use](#)
- 6733991- [AGS proteins and nucleic acid molecules and uses therefor](#)
- 6716982- [Method for preparing camptothecin derivatives](#)
- 6706721- [N-\(3-ethynylphenylamino\)-6,7-bis\(2-methoxyethoxy\)-4-quinazolinamine mesylate anhydrate and monohydrate](#)
- 6586394- [Tissue-derived tumor growth inhibitor](#)
- 6589733- [Methods of preparing compositions comprising chemicals capable of transcriptional modulators](#)
- 6638941- [Conformationally constrained peptidomimetics as .beta.-turn templates and modulators of SH3 domains](#)
- 6664252- [4-aminopyrrolo\[2,3-d\]pyrimidine compounds specific to adenosine A2a receptor and uses](#)

[thereof](#)

- 6673802- [Compounds specific to adenosine A3 receptor and uses thereof](#)
- 6680322- [Compounds specific to adenosine A1 receptors and uses thereof](#)
- 6680324- [Compounds specific to adenosine A1 receptors and uses thereof](#)
- 6686366- [Compounds specific to adenosine A3 receptor and uses thereof](#)
- 6689381- [Liposomal benzoquinazoline thymidylate synthase inhibitor formulations](#)
- 6699894- [Methods for treatment of inflammatory bowel disease](#)
- 7087613- [Treating abnormal cell growth with a stable polymorph of N-\(3-ethynylphenyl\)-6,7-bis\(2-methoxyethoxy\)-4-quinazolinamine hydrochloride](#)
- 7101893- [\(2-Carboxamido\)\(3-amino\)thiophene compounds](#)
- 7498354- [Pyrrolo\[2,3-D\]imidazoles for the treatment of hyperproliferative disorders](#)
- 7501407- [Pyrimidine A.sub.2B selective antagonist compounds, their synthesis and use](#)
- 7504407- [Compounds specific to adenosine A.sub.1 and A.sub.3 receptors and uses thereof](#)
- 7521448- [N-substituted benzimidazolyl c-Kit inhibitors](#)
- 7521456- [N-\(3-ethynylphenyl\)-6,7-bis\(2-methoxyethoxy\)-4-quinazolinamine mesylate anhydrate and monohydrate](#)
- 7524638- [Methods for identification of modulators of OSGPR114 or OSGPR78 activity, and their use in the treatment of disease](#)
- 7524859- [\(2-carboxamido\)\(3-amino\)thiophene compounds](#)
- 7534797- [6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors](#)
- 7566721- [Substituted thienol\[2,3-d\]pyrimidines as kinase inhibitors](#)
- 7598252- [Compounds specific to adenosine A, receptors and uses thereof](#)
- 7485658- [N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors](#)
- 7465726- [Substituted pyrrolo\[2.3-B\]pyridines](#)
- 7459554- [Imidazopyrazine tyrosine kinase inhibitors](#)
- 7115647- [Method of inhibiting neoplastic cells with indole derivatives](#)
- 7144711- [AGS proteins and nucleic acid molecules and uses therefor](#)
- 7160890- [Compounds specific to adenosine A.sub.3 receptor and uses thereof](#)
- 7332493- [Substituted bicyclic derivatives for the treatment of abnormal cell growth](#)
- 7388012- [\(Hydrazido\)\(amino\)thiophene compounds](#)
- 7405210- [Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase](#)
- 7405218- [Isothiazole derivatives useful as anticancer agents](#)
- 7419995- [N-substituted benzimidazolyl c-Kit inhibitors and combinatorial benzimidazole library](#)
- 7429574- [4-heterocyclo-pyrrolo\[2,3d\] pyrimidine compositions and their use](#)
- 7442709- [N3-substituted imidazopyridine c-Kit inhibitors](#)
- 7608577- [Peptidyl ketones as inhibitors of DPIP](#)

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic

- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

